There were several identified compounds targeting PTEN/Akt signalling, such as perifosine and MK-2206, could suppress tumour growth in animal models or clinical trials [90, 91, 93–97]., suggesting that the pharmacological inhibition of PTEN/Akt signalling might be a potential target for the treatment of tumour patients. Here, AKT1 is linked to neoplasm.